Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444245 combined with pembrolizumab in lung cancer and pleural mesothelioma
jRCT2031210286Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pegenzileukin and pembrolizumab in non-small cell lung cancer (NSCLC) and pleural mesothelioma (4 cohorts), sponsored by Sanofi. Primary endpoint: Objective response rate. Started Jan 2022; status: completed.
02
Drugs
pegenzileukinpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)pleural mesothelioma
Beyond the preview
Go deeper on jRCT2031210286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210286.